<DOC>
	<DOCNO>NCT00072384</DOCNO>
	<brief_summary>Phase III trial determine effectiveness combine systemic chemotherapy subtenon carboplatin ophthalmic therapy treat child intraocular retinoblastoma . Drugs use chemotherapy , vincristine , carboplatin , etoposide , work different way stop tumor cell divide stop grow die . It yet know whether systemic chemotherapy subtenon ( conjunctiva eye ) carboplatin combine ophthalmic therapy effective treating intraocular ( within eyeball ) retinoblastoma .</brief_summary>
	<brief_title>Systemic Vincristine , Carboplatin , Etoposide , Subtenon Carboplatin , Local Ophthalmic Therapy Treating Children With Intraocular Retinoblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine event-free survival 12 month pediatric patient ' eye group D intraocular retinoblastoma treat systemic chemotherapy comprise vincristine , carboplatin , etoposide , subtenon carboplatin , local ophthalmic therapy . ( Event define eye individually need nonprotocol therapy include nonprotocol chemotherapy , enucleation external-beam radiation ) SECONDARY OBJECTIVES : I . Determine event-free survival 12 month pediatric patient ' eye group C retinoblastoma treat systemic chemotherapy comprise carboplatin , etoposide , vincristine , subtenon carboplatin , local ophthalmic therapy . II . Determine acute long-term toxic effect regimens patient , include visual outcome incidence secondary malignancy . III . Determine pattern failure patient treat regimen , term vitreous vs retinal v site recurrence . IV . Determine predictor failure include finding study examination anesthesia response status six course chemotherapy . V. Determine percentage group C D eye separately preserve without enucleation fail protocol therapy . OUTLINE : This multicenter study . Patients receive vincristine IV 1 minute day 1 carboplatin IV 1 hour etoposide IV 1 hour day 1 2 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 3 continue blood count recover . Patients receive subtenon carboplatin group C D eye day 0 1 prior course 2-4 . Treatment repeat every 28 day 6 course absence occurrence extraocular retinoblastoma second malignancy . Beginning course 3 systemic chemotherapy , patient undergo local ophthalmic therapy comprise local laser and/or cryotherapy day 1 . Patients follow ophthalmology exam every 4-12 week 3 year age , every 6 month 5 year age , annually 10 year .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis bilateral retinoblastoma least 1 eye group C D intraocular retinoblastoma ophthalmologic examination , define International Classification System Intraocular Retinoblastoma follow : Group C : Discrete localize disease minimal subretinal and/or vitreous seed Subretinal fluid , without prior concurrent seeding , involve ≤ one quarter retina Local fine vitreous seeding may present close discrete tumor Local subretinal seed &lt; 3 mm tumor Group D : Diffuse disease significant vitreous and/or subretinal seeding Tumor ( ) may massive diffuse Subretinal fluid , without prior concurrent seeding , involve total retinal detachment Diffuse massive vitreous disease may include `` greasy '' seed avascular tumor mass Diffuse subretinal seeding may include subretinal plaque tumor nodule Prior enucleation 1 eye allow provide remain eye group C D No tumor present histologic examination cut end optic nerve eye enucleate prior study entry Evidence choroidal and/or optic nerve invasion past lumen cribrosa allow No extraocular retinoblastoma clinically MRI brain orbit without gadolinium CT scan without contrast brain orbit No evidence systemic metastasis bone marrow , lumbar puncture , bone scan , and/or additional test Performance status Karnofsky 50100 % ( 16 year age ) Performance status Lansky 50100 % ( 16 ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2.5 time ULN age Creatinine adjust accord age follow : No great 0.4 mg/dL ( ≤ 5 month ) No great 0.5 mg/dL ( 6 month 11 month ) No great 0.6 mg/dL ( 1 year23 month ) No great 0.8 mg/dL ( 2 years5 year ) No great 1.0 mg/dL ( 6 years9 year ) No great 1.2 mg/dL ( 10 years12 year ) No great 1.4 mg/dL ( 13 year [ female ] ) No great 1.5 mg/dL ( 13 year 15 year [ male ] ) No great 1.7 mg/dL ( 16 year [ male ] ) Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min/1.73m^2 Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test postmenarchal females No prior chemotherapy No concurrent chemotherapy No prior radiotherapy No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>